A prospective study of hepatitis during antituberculous treatment in Taiwanese patients and a review of the literature

Journal of the Formosan Medical Association

Volumn 108, Issue 2, 2009, Pages 102-111

  Sun, Hsin Yun ^a   Chen, In Lon ^b   Gau, Churn Shiouh ^b   Chang, Shan Chwen ^a,b   Luh, Kwen Tay ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antituberculous agents; Hepatitis; Taiwan

Indexed keywords

DICLOFENAC; ETHAMBUTOL; INDINAVIR; ISONIAZID; PARACETAMOL; PREDNISOLONE; PYRAZINAMIDE; RIFAMPICIN; SULFONYLUREA;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; INFECTION RISK; LIVER CIRRHOSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; REVIEW; SIDE EFFECT; TUBERCULOSIS;

EID: 63049112328     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-6646(09)60040-1     Document Type: Article

References (30)

1. Global Tuberculosis Control, 2007. Available at http://www.who.int/tb/publications/global_report/2007/pdf/full.pdf [Date accessed: November 30, 2007]
2. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/ Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-62.
3. Agal S, Baijal R, Pramanik S, et al. Monitoring and management of antituberculosis drug induced hepatotoxicity. J Gastroenterol Hepatol 2005;20:1745-52.
4. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003;37:924-30.
5. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002;35:883-9.
6. Hwang SJ, Wu JC, Lee CN, et al. A prospective clinical study of isoniazid-rifampicin-pyrazinamide-induced liver injury in an area endemic for hepatitis B. J Gastroenterol Hepatol 1997;12:87-91.
7. Wu JC, Lee SD, Yeh PF, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98:502-4.
8. Cho YJ, Lee SM, Yoo CG, et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology 2007;12:401-5.
9. Kwon YS, Koh WJ, Suh GY, et al. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007;131:803-8.
10. Lee BH, Koh WJ, Choi MS, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-11.
11. Shakya R, Rao BS, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004;38:1074-9.
12. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002;166:916-9.
13. Teleman MD, Chee CB, Earnest A, et al. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. Int J Tuberc Lung Dis 2002;6: 699-705.
14. Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201-6.
15. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000;4:256-61.
16. Gulbay BE, Gurkan OU, Yildiz OA, et al. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med 2006;100:1834-42.
17. Fernandez-Villar A, Sopena B, Fernandez-Villar J, et al. The influence of risk factors on the severity of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2004; 8:1499-505.
18. Breen RA, Miller RF, Gorsuch T, et al. Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection. Thorax 2006;61:791-4.
19. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-7.
20. Ungo JR, Jones D, Ashkin D, et al. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med 1998;157:1871-6.
21. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9:2026-30.
22. Dossing M, Wilcke JT, Askgaard DS, et al. Liver injury during antituberculosis treatment: an 11-year study. Tuber Lung Dis 1996;77:335-40.
23. van den Brande P, van Steenbergen W, Vervoort G, et al. Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis. Am J Respir Crit Care Med 1995;152: 1705-8.
24. Ozick LA, Jacob L, Comer GM, et al. Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients. Am J Gastroenterol 1995;90:1978-80.
25. Steele MA, Burk RF, DesPrez RM. Toxic hepatitis with isoniazid and rifampin. A meta-analysis. Chest 1991;99: 465-71.
26. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Joint Tuberculosis Committee of the British Thoracic Society. Thorax 1998;53:536-48.
27. Adverse Drug Reaction Terminology (ART), 1979. Available at http://www.who-umc.org [Date accessed: November 30, 2007]
28. Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996;51:132-6.
29. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52.
30. Chen CH, Yang PM, Huang GT, et al. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 2007;106: 148-55.